[Funding alert] Sano Genetics Secures $11.4 Million in Funding

Sano Genetics secures $11.4 million in funding led by Plural with participation from existing investors including MMC Ventures, Episode 1 and Seedcamp.

Founded by Patrick Short (CEO), Charlotte Guzzo (COO) and William Jones (CTO), Sano Genetics is developing software to enable the precision medicine revolution.

The company combines genetic testing, recruitment, and long-term engagement in one platform, accelerating enrollment and simplifying operations for precision medicine teams driving breakthroughs for patients.

Read also - European Tech Community Upscalers Secures Pre-Seed Funding

The company is seeing early gains from deploying AI to streamline the trial process and delight its customers. The new funding, which brings the total raised to $22M, will be used to meet the growing demand for its products, leverage AI further and expand its reach to more countries, becoming the ultimate precision trial platform.

Medical trials underpin modern healthcare yet clinical research is an incredibly complex and time-consuming process for both patients and companies running trials including pharmaceutical companies and emerging biotech startups.

Reda also - Paris-based Kiln Secures $17m in Funding

Patrick Short, co-founder and CEO of Sano Genetics, said: “Precision medicine is transforming how we think about and approach healthcare, and clinical trials are the bedrock of precision drug development. In the past 12 months, we’ve scaled up our capacity to hold three times more trials than the year before and launched our first programme supporting families affected by ALS. I’m so pleased with everything the team has achieved so far and this new funding will help us to integrate LLMs and other AI tools to drive more productivity. This will help us continue our growth trajectory, particularly with the help of visionary investors like Carina Namih, who supported our seed round and is now supporting us again at Plural.”

Carina Namih, partner at Plural, said: “Precision medicine is going to transform how healthcare is delivered but it needs seamless software tools like Sano Genetics’ to accelerate its impact. My own experience of the difficulty of running clinical trials during my time leading HelixNano helped me understand profoundly just how sorely a platform like Sano Genetics is needed. Patrick and the Sano team have made huge strides in 2023, and I am delighted to be able to continue to support the company to bring faster, more effective clinical trials.”

Charlotte Barttelot, Principal at MMC Ventures, said: "We are excited to back Sano Genetics again after leading its Series A. We continue to see the pull from biopharma for a market-leading infrastructure software to underpin their precision medicine trials which has been evidenced by the strong growth in 2023. We are excited to see this accelerate into 2024."

About Sano Genetics

Sano Genetics’ broad mission is to accelerate the world’s transition to precision medicine. Although accessibility to DNA sequencing has surged in the past decade, precision medicine studies have failed to keep up. They are still complex, time-consuming and costly, and many potentially life-changing treatments never see daylight.

Read also - Huntingdon-based HutanBio Secures £2.25M in Funding